Genes, circuits, and precision therapies for autism and related neurodevelopmental disorders

Science

Volumn 350, Issue 6263, 2015, Pages

  Sahin, Mustafa ^a   Sur, Mriganka ^b  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHYL 6 (5 METHYL 3 PHENYL 4 ISOXAZOLYLMETHOXY)PYRIDINE; ACAMPROSATE; ARIPIPRAZOLE; BIOLOGICAL MARKER; DEXTROMETHORPHAN; DONEPEZIL; EPIGALLOCATECHIN GALLATE; EVEROLIMUS; FINGOLIMOD; FOLINIC ACID; GANAXOLONE; GLATIRAMER; METADOXINE; MINOCYCLINE; NICOTINE; RECOMBINANT SOMATOMEDIN C; RISPERIDONE; THYROID HORMONE; TROFINETIDE;

GENE EXPRESSION; GENE TRANSFER; GENETICS; HETEROGENEITY; NERVOUS SYSTEM DISORDER; NEUROLOGY; PROTEIN; RISK FACTOR;

AUTISM; BASAL GANGLION; BEHAVIOR; BRAIN CORTEX; BRAIN DISEASE; BRAIN REGION; CELL COMMUNICATION; CEREBELLUM; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIAL (TOPIC); COMORBIDITY; DOWN SYNDROME; EPIGENETICS; FRAGILE X SYNDROME; GENE IDENTIFICATION; GENE MUTATION; GENETIC HETEROGENEITY; GENETIC REGULATION; HAPPY PUPPET SYNDROME; HIPPOCAMPUS; HUMAN; HYPOTHALAMUS; MEDICINE; NERVE CELL NETWORK; NEURODEVELOPMENTAL DISORDER; PHELAN MCDERMID SYNDROME; PRECISION MEDICINE; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SYNTHESIS; RETT SYNDROME; REVIEW; RISK FACTOR; SIGNAL TRANSDUCTION; SYNAPTIC SIGNALING; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; TUBEROUS SCLEROSIS; ANIMAL; AUTISTIC DISORDER; BRAIN; GENE; GENETIC EPIGENESIS; GENETIC PREDISPOSITION; GENETIC TRANSCRIPTION; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MOUSE; MUTATION; NERVE TRACT; NEURODEVELOPMENTAL DISORDERS; PERSONALIZED MEDICINE; PROCEDURES;

ANIMALS; AUTISTIC DISORDER; BEHAVIOR; BRAIN; CHROMATIN ASSEMBLY AND DISASSEMBLY; CLINICAL TRIALS AS TOPIC; EPIGENESIS, GENETIC; GENES; GENETIC PREDISPOSITION TO DISEASE; HUMANS; METABOLIC NETWORKS AND PATHWAYS; MICE; MUTATION; NEURAL PATHWAYS; NEURODEVELOPMENTAL DISORDERS; PRECISION MEDICINE; PROTEIN BIOSYNTHESIS; TRANSCRIPTION, GENETIC; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84947746397     PISSN: 00368075     EISSN: 10959203     Source Type: Journal    
DOI: 10.1126/science.aab3897     Document Type: Review

References (118)

1. L. Kanner, Autistic disturbances of affective contact. Nerv. Child 2, 217-250 (1943).
2. C. Lord, in Understanding Autism: From Basic Neuroscience to Treatment, S. O. Moldin, J. L. R. Rubenstein, Ed. (Taylor & Francis, Boca Raton, FL, 2006), pp. 1-23.
3. M. Ganz, in Understanding Autism: From Basic Neuroscience to Treatment, S. O. Moldin, J. L. R. Rubenstein, Ed. (Taylor & Francis, Boca Raton, FL, 2006), pp. 475-502.
4. G. Vivanti, J. Barbaro, K. Hudry, C. Dissanayake, M. Prior, Intellectual development in autism spectrum disorders: New insights from longitudinal studies. Front. Hum. Neurosci. 7, 354 (2013). doi: 10.3389/fnhum.2013.00354; pmid: 23847518
5. C. Gillberg, E. Fernell, Autism plus versus autism pure. J. Autism Dev. Disord. 44, 3274-3276 (2014). doi: 10.1007/s10803-014-2163-1; pmid: 24958434
6. D. Ebrahimi-Fakhari, M. Sahin, Autism and the synapse: Emerging mechanisms and mechanism-based therapies. Curr. Opin. Neurol. 28, 91-102 (2015). doi: 10.1097/WCO.0000000000000186; pmid: 25695134
7. B. J. Casey, M. E. Oliveri, T. Insel, A neurodevelopmental perspective on the research domain criteria (RDoC) framework. Biol. Psychiatry 76, 350-353 (2014). doi: 10.1016/j.biopsych.2014.01.006; pmid: 25103538
8. T. Insel et al., Research domain criteria (RDoC): Toward a new classification framework for research on mental disorders. Am. J. Psychiatry 167, 748-751 (2010). doi: 10.1176/appi.ajp. 2010.09091379; pmid: 20595427
9. D. H. Geschwind, M. W. State, Gene hunting in autism spectrum disorder: On the path to precision medicine. Lancet Neurol. (2015). doi: 10.1016/S1474-4422 (15) 00044-7; pmid: 25891009
10. S. Ripke et al., Biological insights from 108 schizophreniaassociated genetic loci. Nature 511, 421-427 (2014). doi: 10.1038/nature13595; pmid: 25056061
11. A. Poduri, G. D. Evrony, X. Cai, C. A. Walsh, Somatic mutation, genomic variation, and neurological disease. Science 341, 1237758 (2013). doi: 10.1126/science.1237758; pmid: 23828942
12. T. W. Yu et al., Using whole-exome sequencing to identify inherited causes of autism. Neuron 77, 259-273 (2013). pmid: 23352163
13. E. M. Morrow et al., Identifying autism loci and genes by tracing recent shared ancestry. Science 321, 218-223 (2008). doi: 10.1126/science.1157657; pmid: 18621663
14. T. N. Turner et al., Loss of d-catenin function in severe autism. Nature 520, 51-56 (2015). doi: 10.1038/nature14186; pmid: 25807484
15. C. Limperopoulos et al., Does cerebellar injury in premature infants contribute to the high prevalence of long-term cognitive, learning, and behavioral disability in survivors? Pediatrics 120, 584-593 (2007). doi: 10.1542/peds.2007-1041; pmid: 17766532
16. C. Limperopoulos, G. Chilingaryan, N. Guizard, R. L. Robertson, A. J. Du Plessis, Cerebellar injury in the premature infant is associated with impaired growth of specific cerebral regions. Pediatr. Res. 68, 145-150 (2010). doi: 10.1203/PDR.0b013e3181e1d032; pmid: 20389260
17. L. Shi, S. H. Fatemi, R. W. Sidwell, P. H. Patterson, Maternal influenza infection causes marked behavioral and pharmacological changes in the offspring. J. Neurosci. 23, 297-302 (2003). pmid: 12514227
18. P. H. Patterson, Immune involvement in schizophrenia and autism: Etiology, pathology and animal models. Behav. Brain Res. 204, 313-321 (2009). doi: 10.1016/j.bbr.2008.12.016; pmid: 19136031
19. P. A. Garay, A. K. McAllister, Novel roles for immune molecules in neural development: Implications for neurodevelopmental disorders. Front Synaptic Neurosci 2, 136 (2010). doi: 10.3389/fnsyn. 2010.00136; pmid: 21423522
20. K. Garbett et al., Immune transcriptome alterations in the temporal cortex of subjects with autism. Neurobiol. Dis. 30, 303-311 (2008). doi: 10.1016/j.nbd.2008.01.012; pmid: 18378158
21. D. L. Vargas, C. Nascimbene, C. Krishnan, A. W. Zimmerman, C. A. Pardo, Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann. Neurol. 57, 67-81 (2005). doi: 10.1002/ana.20315; pmid: 15546155
22. P. A. Garay, E. Y. Hsiao, P. H. Patterson, A. K. McAllister, Maternal immune activation causes age- and region-specific changes in brain cytokines in offspring throughout development. Brain Behav. Immun. 31, 54-68 (2013). doi: 10.1016/j.bbi.2012.07.008; pmid: 22841693
23. R. K. Weir et al., Preliminary evidence of neuropathology in nonhuman primates prenatally exposed to maternal immune activation. Brain Behav. Immun. 48, 139-146 (2015). doi: 10.1016/j.bbi.2015.03.009; pmid: 25816799
24. D. Ehninger et al., Gestational immune activation and Tsc2 haploinsufficiency cooperate to disrupt fetal survival and may perturb social behavior in adult mice. Mol. Psychiatry 17, 62-70 (2012). doi: 10.1038/mp. 2010.115; pmid: 21079609
25. J. G. Mulle, W. G. Sharp, J. F. Cubells, The gut microbiome: A new frontier in autism research. Curr. Psychiatry Rep. 15, 337 (2013). doi: 10.1007/s11920-012-0337-0; pmid: 23307560
26. D. W. Kang et al., Reduced incidence of Prevotella and other fermenters in intestinal microflora of autistic children. PLOS ONE 8, e68322 (2013). pmid: 23844187
27. E. Y. Hsiao et al., Microbiota modulate behavioral and physiological abnormalities associated with neurodevelopmental disorders. Cell 155, 1451-1463 (2013). doi: 10.1016/j.cell.2013.11.024; pmid: 24315484
28. R. J. Kelleher 3rd, M. F. Bear, The autistic neuron: Troubled translation? Cell 135, 401-406 (2008). doi: 10.1016/j.cell.2008.10.017; pmid: 18984149
29. H. Y. Zoghbi, M. F. Bear, Synaptic dysfunction in neurodevelopmental disorders associated with autism and intellectual disabilities. Cold Spring Harb. Perspect. Biol. 4, a009886 (2012). doi: 10.1101/cshperspect.a009886; pmid: 22258914
30. T. C. Südhof, Neuroligins and neurexins link synaptic function to cognitive disease. Nature 455, 903-911 (2008). doi: 10.1038/nature07456; pmid: 18923512
31. I. Iossifov et al., De novo gene disruptions in children on the autistic spectrum. Neuron 74, 285-299 (2012). doi: 10.1016/j.neuron. 2012.04.009; pmid: 22542183
32. R. Bernier et al., Disruptive CHD8 mutations define a subtype of autism early in development. Cell 158, 263-276 (2014). doi: 10.1016/j.cell.2014.06.017; pmid: 24998929
33. J. Castro, N. Mellios, M. Sur, Mechanisms and therapeutic challenges in autism spectrum disorders: Insights from Rett syndrome. Curr. Opin. Neurol. 26, 154-159 (2013). doi: 10.1097/WCO.0b013e32835f19a7; pmid: 23449173
34. X. Nan, F. J. Campoy, A. Bird, MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin. Cell 88, 471-481 (1997). doi: 10.1016/S0092-8674 (00) 81887-5; pmid: 9038338
35. R. R. Meehan, J. D. Lewis, A. P. Bird, Characterization of MeCP2, a vertebrate DNA binding protein with affinity for methylated DNA. Nucleic Acids Res. 20, 5085-5092 (1992). doi: 10.1093/nar/20.19.5085; pmid: 1408825
36. P. L. Jones et al., Methylated DNA and MeCP2 recruit histone deacetylase to repress transcription. Nat. Genet. 19, 187-191 (1998). doi: 10.1038/561; pmid: 9620779
37. M. Chahrour et al., MeCP2, a key contributor to neurological disease, activates and represses transcription. Science 320, 1224-1229 (2008). doi: 10.1126/science.1153252; pmid: 18511691
38. S. Ben-Shachar, M. Chahrour, C. Thaller, C. A. Shaw, H. Y. Zoghbi, Mouse models of MeCP2 disorders share gene expression changes in the cerebellum and hypothalamus. Hum. Mol. Genet. 18, 2431-2442 (2009). doi: 10.1093/hmg/ddp181; pmid: 19369296
39. R. G. Urdinguio et al., Disrupted microRNA expression caused by Mecp2 loss in a mouse model of Rett syndrome. Epigenetics 5, 656-663 (2010). doi: 10.4161/epi.5.7.13055; pmid: 20716963
40. H. Wu et al., Genome-wide analysis reveals methyl-CpGbinding protein 2-dependent regulation of microRNAs in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 107, 18161-18166 (2010). doi: 10.1073/pnas.1005595107; pmid: 20921386
41. P. Jin et al., Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat. Neurosci. 7, 113-117 (2004). doi: 10.1038/nn1174; pmid: 14703574
42. J. O. Lipton, M. Sahin, The neurology of mTOR. Neuron 84, 275-291 (2014). doi: 10.1016/j.neuron. 2014.09.034; pmid: 25374355
43. M. Qin et al., Altered cerebral protein synthesis in fragile X syndrome: Studies in human subjects and knockout mice. J. Cereb. Blood Flow Metab. 33, 499-507 (2013). doi: 10.1038/jcbfm.2012.205; pmid: 23299245
44. J. C. Darnell et al., FMRP stalls ribosomal translocation on mRNAs linked to synaptic function and autism. Cell 146, 247-261 (2011). doi: 10.1016/j.cell.2011.06.013; pmid: 21784246
45. Q. Chang, G. Khare, V. Dani, S. Nelson, R. Jaenisch, The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression. Neuron 49, 341-348 (2006). doi: 10.1016/j.neuron. 2005.12.027; pmid: 16446138
46. D. Tropea et al., Partial reversal of Rett Syndrome-like symptoms in MeCP2 mutant mice. Proc. Natl. Acad. Sci. U. S. A. 106, 2029-2034 (2009). doi: 10.1073/pnas.0812394106; pmid: 19208815
47. N. Mellios et al., b2-Adrenergic receptor agonist ameliorates phenotypes and corrects microRNA-mediated IGF1 deficits in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 111, 9947-9952 (2014). doi: 10.1073/pnas.1309426111; pmid: 24958851
48. J. Castro et al., Functional recovery with recombinant human IGF1 treatment in a mouse model of Rett Syndrome. Proc. Natl. Acad. Sci. U. S. A. 111, 9941-9946 (2014). doi: 10.1073/pnas.1311685111; pmid: 24958891
49. S. Ricciardi et al., Reduced AKT/mTOR signaling and protein synthesis dysregulation in a Rett syndrome animal model. Hum. Mol. Genet. 20, 1182-1196 (2011). doi: 10.1093/hmg/ddq563; pmid: 21212100
50. M. C. Marchetto et al., A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells. Cell 143, 527-539 (2010). doi: 10.1016/j.cell.2010.10.016; pmid: 21074045
51. Y. Li et al., Global transcriptional and translational repression in human-embryonic-stem-cell-derived Rett syndrome neurons. Cell Stem Cell 13, 446-458 (2013). doi: 10.1016/j.stem.2013.09.001; pmid: 24094325
52. O. S. Khwaja et al., Safety, pharmacokinetics, and preliminary assessment of efficacy of mecasermin (recombinant human IGF-1) for the treatment of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 111, 4596-4601 (2014). doi: 10.1073/pnas.1311141111; pmid: 24623853
53. A. Shcheglovitov et al., SHANK3 and IGF1 restore synaptic deficits in neurons from 22q13 deletion syndrome patients. Nature 503, 267-271 (2013). pmid: 24132240
54. O. Bozdagi, T. Tavassoli, J. D. Buxbaum, Insulin-like growth factor-1 rescues synaptic and motor deficits in a mouse model of autism and developmental delay. Mol. Autism 4, 9 (2013). doi: 10.1186/2040-2392-4-9; pmid: 23621888
55. A. Bhattacharya et al., Genetic removal of p70 S6 kinase 1 corrects molecular, synaptic, and behavioral phenotypes in fragile X syndrome mice. Neuron 76, 325-337 (2012). doi: 10.1016/j.neuron. 2012.07.022; pmid: 23083736
56. T. Udagawa et al., Genetic and acute CPEB1 depletion ameliorate fragile X pathophysiology. Nat. Med. 19, 1473-1477 (2013). doi: 10.1038/nm.3353; pmid: 24141422
57. C. Gross et al., Selective role of the catalytic PI3K subunit p110b in impaired higher order cognition in fragile X syndrome. Cell Rep. 11, 681-688 (2015). doi: 10.1016/j.celrep. 2015.03.065; pmid: 25921527
58. C. Gross et al., Increased expression of the PI3K enhancer PIKE mediates deficits in synaptic plasticity and behavior in fragile X syndrome. Cell Rep. 11, 727-736 (2015). doi: 10.1016/j.celrep. 2015.03.060; pmid: 25921541
59. K. M. Huber, M. S. Kayser, M. F. Bear, Role for rapid dendritic protein synthesis in hippocampal mGluR-dependent long-term depression. Science 288, 1254-1256 (2000). doi: 10.1126/science.288.5469.1254; pmid: 10818003
60. K. M. Huber, S. M. Gallagher, S. T. Warren, M. F. Bear, Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U. S. A. 99, 7746-7750 (2002). doi: 10.1073/pnas.122205699; pmid: 12032354
61. D. Tian et al., Contribution of mGluR5 to pathophysiology in a mouse model of human chromosome 16p11.2 microdeletion. Nat. Neurosci. 18, 182-184 (2015). doi: 10.1038/nn. 3911; pmid: 25581360
62. S. J. Baudouin et al., Shared synaptic pathophysiology in syndromic and nonsyndromic rodent models of autism. Science 338, 128-132 (2012). doi: 10.1126/science.1224159; pmid: 22983708
63. A. A. Scott-Van Zeeland et al., Altered functional connectivity in frontal lobe circuits is associated with variation in the autism risk gene CNTNAP2. Sci. Transl. Med. 2, 56ra80 (2010). doi: 10.1126/scitranslmed.3001344; pmid: 21048216
64. J. M. Peters et al., Loss of white matter microstructural integrity is associated with adverse neurological outcome in tuberous sclerosis complex. Acad. Radiol. 19, 17-25 (2012). doi: 10.1016/j.acra.2011.08.016; pmid: 22142677
65. A. J. Willsey et al., Coexpression networks implicate human midfetal deep cortical projection neurons in the pathogenesis of autism. Cell 155, 997-1007 (2013). doi: 10.1016/j.cell.2013.10.020; pmid: 24267886
66. N. N. Parikshak et al., Integrative functional genomic analyses implicate specific molecular pathways and circuits in autism. Cell 155, 1008-1021 (2013). doi: 10.1016/j.cell.2013.10.031; pmid: 24267887
67. N. Gogolla et al., Common circuit defect of excitatoryinhibitory balance in mouse models of autism. J. Neurodev. Disord. 1, 172-181 (2009). doi: 10.1007/s11689-009-9023-x; pmid: 20664807
68. M. Wöhr et al., Lack of parvalbumin in mice leads to behavioral deficits relevant to all human autism core symptoms and related neural morphofunctional abnormalities. Transl. Psychiatry 5, e525 (2015). doi: 10.1038/tp. 2015.19; pmid: 25756808
69. Y. A. Lawrence, T. L. Kemper, M. L. Bauman, G. J. Blatt, Parvalbumin-, calbindin-, and calretinin-immunoreactive hippocampal interneuron density in autism. Acta Neurol. Scand. 121, 99-108 (2010). doi: 10.1111/j.1600-0404.2009.01234.x; pmid: 19719810
70. D. Vogt, K. K. Cho, A. T. Lee, V. S. Sohal, J. L. Rubenstein, The parvalbumin/somatostatin ratio is increased in Pten mutant mice and by human PTEN ASD alleles. Cell Rep. 11, 944-956 (2015). doi: 10.1016/j.celrep. 2015.04.019; pmid: 25937288
71. D. Goffin, E. S. Brodkin, J. A. Blendy, S. J. Siegel, Z. Zhou, Cellular origins of auditory event-related potential deficits in Rett syndrome. Nat. Neurosci. 17, 804-806 (2014). doi: 10.1038/nn. 3710; pmid: 24777420
72. H. T. Chao et al., Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 468, 263-269 (2010). doi: 10.1038/nature09582; pmid: 21068835
73. J. L. Rubenstein, M. M. Merzenich, Model of autism: Increased ratio of excitation/inhibition in key neural systems. Genes Brain Behav. 2, 255-267 (2003). doi: 10.1034/j.1601-183X.2003.00037.x; pmid: 14606691
74. G. Calfa, W. Li, J. M. Rutherford, L. Pozzo-Miller, Excitation/inhibition imbalance and impaired synaptic inhibition in hippocampal area CA3 of Mecp2 knockout mice. Hippocampus 25, 159-168 (2015). doi: 10.1002/hipo.22360; pmid: 25209930
75. V. S. Dani et al., Reduced cortical activity due to a shift in the balance between excitation and inhibition in a mouse model of Rett syndrome. Proc. Natl. Acad. Sci. U. S. A. 102, 12560-12565 (2005). doi: 10.1073/pnas.0506071102; pmid: 16116096
76. H. T. Chao, H. Y. Zoghbi, C. Rosenmund, MeCP2 controls excitatory synaptic strength by regulating glutamatergic synapse number. Neuron 56, 58-65 (2007). doi: 10.1016/j.neuron. 2007.08.018; pmid: 17920015
77. L. Wood, N. W. Gray, Z. Zhou, M. E. Greenberg, G. M. Shepherd, Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in an RNA interference model of methyl-CpG-binding protein 2 deficiency. J. Neurosci. 29, 12440-12448 (2009). doi: 10.1523/JNEUROSCI.3321-09.2009; pmid: 19812320
78. Y. Ben-Ari, J. L. Gaiarsa, R. Tyzio, R. Khazipov, GABA: A pioneer transmitter that excites immature neurons and generates primitive oscillations. Physiol. Rev. 87, 1215-1284 (2007). doi: 10.1152/physrev. 00017.2006; pmid: 17928584
79. J. Blundell et al., Neuroligin-1 deletion results in impaired spatial memory and increased repetitive behavior. J. Neurosci. 30, 2115-2129 (2010). doi: 10.1523/JNEUROSCI.4517-09.2010; pmid: 20147539
80. P. E. Rothwell et al., Autism-associated neuroligin-3 mutations commonly impair striatal circuits to boost repetitive behaviors. Cell 158, 198-212 (2014). doi: 10.1016/j.cell.2014.04.045; pmid: 24995986
81. J. Peça et al., Shank3 mutant mice display autistic-like behaviours and striatal dysfunction. Nature 472, 437-442 (2011). doi: 10.1038/nature09965; pmid: 21423165
82. M. L. Bauman, T. L. Kemper, Neuroanatomic observations of the brain in autism: A review and future directions. Int. J. Dev. Neurosci. 23, 183-187 (2005). doi: 10.1016/j.ijdevneu.2004.09.006; pmid: 15749244
83. M. F. Casanova, The neuropathology of autism. Brain Pathol. 17, 422-433 (2007). doi: 10.1111/j.1750-3639.2007.00100.x; pmid: 17919128
84. S. H. Fatemi et al., Consensus paper: Pathological role of the cerebellum in autism. Cerebellum 11, 777-807 (2012). pmid: 22370873
85. E. R. Whitney, T. L. Kemper, M. L. Bauman, D. L. Rosene, G. J. Blatt, Cerebellar Purkinje cells are reduced in a subpopulation of autistic brains: A stereological experiment using calbindin-D28k. Cerebellum 7, 406-416 (2008). doi: 10.1007/s12311-008-0043-y; pmid: 18587625
86. E. Courchesne, R. Yeung-Courchesne, G. A. Press, J. R. Hesselink, T. L. Jernigan, Hypoplasia of cerebellar vermal lobules VI and VII in autism. N. Engl. J. Med. 318, 1349-1354 (1988). doi: 10.1056/NEJM198805263182102; pmid: 3367935
87. D. G. Amaral, C. M. Schumann, C. W. Nordahl, Neuroanatomy of autism. Trends Neurosci. 31, 137-145 (2008). doi: 10.1016/j.tins.2007.12.005; pmid: 18258309
88. W. R. Kates et al., Neuroanatomic variation in monozygotic twin pairs discordant for the narrow phenotype for autism. Am. J. Psychiatry 161, 539-546 (2004). doi: 10.1176/appi.ajp. 161.3.539; pmid: 14992981
89. N. Akshoomoff et al., Outcome classification of preschool children with autism spectrum disorders using MRI brain measures. J. Am. Acad. Child Adolesc. Psychiatry 43, 349-357 (2004). doi: 10.1097/00004583-200403000-00018; pmid: 15076269
90. G. Allen, E. Courchesne, Differential effects of developmental cerebellar abnormality on cognitive and motor functions in the cerebellum: An fMRI study of autism. Am. J. Psychiatry 160, 262-273 (2003). doi: 10.1176/appi.ajp. 160.2.262; pmid: 12562572
91. E. Asano et al., Autism in tuberous sclerosis complex is related to both cortical and subcortical dysfunction. Neurology 57, 1269-1277 (2001). doi: 10.1212/WNL.57.7.1269; pmid: 11591847
92. R. M. Reith et al., Loss of Tsc2 in Purkinje cells is associated with autistic-like behavior in a mouse model of tuberous sclerosis complex. Neurobiol. Dis. 51, 93-103 (2013). doi: 10.1016/j.nbd.2012.10.014; pmid: 23123587
93. P. T. Tsai et al., Autistic-like behaviour and cerebellar dysfunction in Purkinje cell Tsc1 mutant mice. Nature 488, 647-651 (2012). doi: 10.1038/nature11310; pmid: 22763451
94. A. V. Molofsky et al., Astrocytes and disease: A neurodevelopmental perspective. Genes Dev. 26, 891-907 (2012). doi: 10.1101/gad.188326.112; pmid: 22549954
95. C. Eroglu, B. A. Barres, Regulation of synaptic connectivity by glia. Nature 468, 223-231 (2010). doi: 10.1038/nature09612; pmid: 21068831
96. J. Schummers, H. Yu, M. Sur, Tuned responses of astrocytes and their influence on hemodynamic signals in the visual cortex. Science 320, 1638-1643 (2008). doi: 10.1126/science.1156120; pmid: 18566287
97. N. Chen et al., Nucleus basalis-enabled stimulus-specific plasticity in the visual cortex is mediated by astrocytes. Proc. Natl. Acad. Sci. U. S. A. 109, E2832-E2841 (2012). doi: 10.1073/pnas.1206557109; pmid: 23012414
98. P. G. Haydon, M. Nedergaard, How do astrocytes participate in neural plasticity? Cold Spring Harb. Perspect. Biol. 7, a020438 (2015). doi: 10.1101/cshperspect.a020438; pmid: 25502516
99. D. H. Yasui et al., MeCP2 modulates gene expression pathways in astrocytes. Mol. Autism 4, 3 (2013). doi: 10.1186/2040-2392-4-3; pmid: 23351786
100. H. Higashimori et al., Astroglial FMRP-dependent translational down-regulation of mGluR5 underlies glutamate transporter GLT1 dysregulation in the fragile X mouse. Hum. Mol. Genet. 22, 2041-2054 (2013). doi: 10.1093/hmg/ddt055; pmid: 23396537
101. D. T. Lioy et al., A role for glia in the progression of Rett's syndrome. Nature 475, 497-500 (2011). doi: 10.1038/nature10214; pmid: 21716289
102. A. L. Xavier, J. R. Menezes, S. A. Goldman, M. Nedergaard, Fine-tuning the central nervous system: Microglial modelling of cells and synapses. Philos. Trans. R. Soc. London B Biol. Sci. 369, 20130593 (2014). doi: 10.1098/rstb.2013.0593; pmid: 25225087
103. D. P. Schafer, E. K. Lehrman, B. Stevens, The "quad-partite" synapse: Microglia-synapse interactions in the developing and mature CNS. Glia 61, 24-36 (2013). doi: 10.1002/glia.22389; pmid: 22829357
104. N. C. Derecki et al., Wild-type microglia arrest pathology in a mouse model of Rett syndrome. Nature 484, 105-109 (2012). doi: 10.1038/nature10907; pmid: 22425995
105. J. Wang et al., Wild-type microglia do not reverse pathology in mouse models of Rett syndrome. Nature 521, E1-E4 (2015). doi: 10.1038/nature14444; pmid: 25993969
106. B. D. Auerbach, E. K. Osterweil, M. F. Bear, Mutations causing syndromic autism define an axis of synaptic pathophysiology. Nature 480, 63-68 (2011). doi: 10.1038/nature10658; pmid: 22113615
107. J. Guy, J. Gan, J. Selfridge, S. Cobb, A. Bird, Reversal of neurological defects in a mouse model of Rett syndrome. Science 315, 1143-1147 (2007). doi: 10.1126/science.1138389; pmid: 17289941
108. A. Michalon et al., Chronic pharmacological mGlu5 inhibition corrects fragile X in adult mice. Neuron 74, 49-56 (2012). doi: 10.1016/j.neuron. 2012.03.009; pmid: 22500629
109. D. Ehninger et al., Reversal of learning deficits in a Tsc2+/-mouse model of tuberous sclerosis. Nat. Med. 14, 843-848 (2008). doi: 10.1038/nm1788; pmid: 18568033
110. D. D. Krueger, M. F. Bear, Toward fulfilling the promise of molecular medicine in fragile X syndrome. Annu. Rev. Med. 62, 411-429 (2011). doi: 10.1146/annurev-med-061109-134644; pmid: 21090964
111. S. H. Scharf, G. Jaeschke, J. G. Wettstein, L. Lindemann, Metabotropic glutamate receptor 5 as drug target for Fragile X syndrome. Curr. Opin. Pharmacol. 20, 124-134 (2015). doi: 10.1016/j.coph.2014.11.004; pmid: 25488569
112. J. L. Silverman, M. Yang, C. Lord, J. N. Crawley, Behavioural phenotyping assays for mouse models of autism. Nat. Rev. Neurosci. 11, 490-502 (2010). doi: 10.1038/nrn2851; pmid: 20559336
113. B. C. Reeb-Sutherland, N. A. Fox, Eyeblink conditioning: A non-invasive biomarker for neurodevelopmental disorders. J. Autism Dev. Disord. 45, 376-394 (2015). doi: 10.1007/s10803-013-1905-9; pmid: 23942847
114. M. J. Gandal et al., Validating g oscillations and delayed auditory responses as translational biomarkers of autism. Biol. Psychiatry 68, 1100-1106 (2010). doi: 10.1016/j.biopsych.2010.09.031; pmid: 21130222
115. S. Durand et al., NMDA receptor regulation prevents regression of visual cortical function in the absence of Mecp2. Neuron 76, 1078-1090 (2012). doi: 10.1016/j.neuron. 2012.12.004; pmid: 23259945
116. M. Kondo et al., Environmental enrichment ameliorates a motor coordination deficit in a mouse model of Rett syndrome-Mecp2 gene dosage effects and BDNF expression. Eur. J. Neurosci. 27, 3342-3350 (2008). doi: 10.1111/j.1460-9568.2008.06305.x; pmid: 18557922
117. L. Restivo et al., Enriched environment promotes behavioral and morphological recovery in a mouse model for the fragile X syndrome. Proc. Natl. Acad. Sci. U. S. A. 102, 11557-11562 (2005). doi: 10.1073/pnas.0504984102; pmid: 16076950
118. S. L. Fyffe et al., Deletion of Mecp2 in Sim1-expressing neurons reveals a critical role for MeCP2 in feeding behavior, aggression, and the response to stress. Neuron 59, 947-958 (2008). doi: 10.1016/j.neuron. 2008.07.030; pmid: 18817733